Lilly wins ban of generic Strattera pending appeal
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
Previous Top Honorees are not eligible for nomination. Remaining honorees are eligible. 2022 Not-For-Profit Mark Kern, Chief Financial Officer, Firefly Children and Family Alliance – Top Honoree Michael E. Johnson, Chief Financial Officer, CICOA Aging & In-Home, Solutions Inc. Jenny Skehan, Chief Financial Officer, Girl Scouts of Central Indiana Government Schools Brian Tomamichel, Assistant Superintendent […]
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
In the last 10 years, Indiana’s major research universities—Indiana and Purdue—have nearly doubled their
science-based research budgets, to a total of $895 million. Yet Indiana’s public universities still run in the middle
of the pack nationally.
Flanner and Buchanan Funeral Centers sometimes stretches the definition of “funeral” to stay relevant after nearly
130 years. The family-owned business began downtown and has grown northward along with the city’s population. Today,
it has 14 funeral centers and conducted 2,200 funerals last year.
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
Dr. Daniel Kraft has joined Riley Hospital for Children to oversee Riley’s new sports medicine program
for young athletes. Kraft most recently served as the founder and director of the Youth Sports Medicine Institute at Methodist
Sports Medicine—The Orthopedic Specialists. Both Riley and Methodist are owned by Indianapolis-based Clarian Health.
Dr. Jennifer Eikenberry and Dr. Amy M. Waddell have joined the Eugene and Marilyn Glick
Eye Institute at the Indiana University School of Medicine. Eikenberry will see patients at the University Hospital clinic.
Waddell will see patients at the Wishard Memorial Hospital clinic. Both were residents in the IU medical school’s department
of ophthalmology.
Catherine A. Clements has joined the health and life sciences practice group at Baker & Daniels LLP.
Clements earned her law degree in 2009 from Indiana University in Bloomington. Before that, she helped develop clinical trials
at Eli Lilly and Co. and the Roudebush Veterans Affairs Medical Center in Indianapolis.
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
Indiana’s unemployment rate increased by a sliver, to 10.2 percent, in July despite increases in jobs in many industries.
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.
Many people in our community, state, country and around the globe need our help. The numbers are staggering.
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.